Emerging Cytomegalovirus Management Strategies After Solid Organ Transplantation: Challenges and Opportunities

Papers of particular interest, published recently have been highlighted as: • Of importance

1. 1.
   Staras SA et al. Cytomegalovirus seroprevalence and childhood sources of infection: A population-based study among pre-adolescents in the United States. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2008;43(3):266–71.CrossRefGoogle Scholar
2. 2.
   Staras SA et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2006;43(9):1143–51.CrossRefGoogle Scholar
3. 3.
   Gorsane I et al. Cytomegalovirus ischemic colitis and transverse myelitis in a renal transplant recipient. Saudi J Kidney Dis Transplant: Off Publ Saudi Center Organ Transplant Saudi Arabia. 2013;24(2):309–14.CrossRefGoogle Scholar
4. 4.
   Papasotiriou M et al. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient. Clin Nephrol. 2013;80(1):75–8.PubMedCrossRefGoogle Scholar
5. 5.
   Riediger C et al. Cytomegalovirus infection of the major duodenal papilla in a renal allograft recipient with severe biliary obstruction and acalculous cholecystitis. Transplant Infect Dis: Off J Transplant Soc. 2013;15(4):E129–33.CrossRefGoogle Scholar
6. 6.
   Gotthardt DN et al. Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2013;19(10):1142–50.Google Scholar
7. 7.
   Milan A et al. Identification of bacterial infections and clinical manifestation associated with cytomegalovirus in liver transplantation patients. Transplant Proc. 2013;45(3):1130–2.PubMedCrossRefGoogle Scholar
8. 8.
   Giakoustidis D et al. Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center. Transplant Proc. 2012;44(9):2715–7.PubMedCrossRefGoogle Scholar
9. 9.
   Le Page, A.K., et al., Cytomegalovirus & Epstein Barr Virus Serostatus as a predictor of the long term Outcome of Kidney Transplantation. Nephrology, 2013.Google Scholar
10. 10.
    San-Juan R et al. Limited impact of cytomegalovirus infection in the long-term outcome of renal and liver transplant. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2013;56(4):316–22.CrossRefGoogle Scholar
11. 11.
    Elfadawy, N., et al., CMV Viremia Is Associated With a Decreased Incidence of BKV Reactivation after Kidney and Kidney-Pancreas Transplantation. Transplantation, 2013.Google Scholar
12. 12.
    Gatault P et al. CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(8):2119–29.CrossRefGoogle Scholar
13. 13.
    Harvala H et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893–8.PubMedCrossRefGoogle Scholar
14. 14.
    Fallatah SM et al. Cytomegalovirus infection post-pancreas-kidney transplantation–results of antiviral prophylaxis in high-risk patients. Clin Transpl. 2013;27(4):503–9.CrossRefGoogle Scholar
15. 15.
    Bhadauria D et al. Cytomegalovirus disease in renal transplant recipients: a single-center experience. Indian J Microbiol. 2012;52(3):510–5.PubMedCentralPubMedCrossRefGoogle Scholar
16. 16.
    Luan FL. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction. Transplant Proc. 2013;45(1):175–7.PubMedCrossRefGoogle Scholar
17. 17.
    Ghassemieh B et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 2013;32(7):701–6.CrossRefGoogle Scholar
18. 18.
    Kobashigawa J et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transplant Infect Dis: Off J Transplant Soc. 2013;15(2):150–62.CrossRefGoogle Scholar
19. 19.
    Havenith SH et al. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation. 2013;95(1):184–91.PubMedCrossRefGoogle Scholar
20. 20.
    Pang XL et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(2):258–68.CrossRefGoogle Scholar
21. 21.
    Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26(4):703–27.PubMedCrossRefGoogle Scholar
22. 22.•
    Hirsch HH et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56(3):367–73. This study, which compared the performance characteristics of CMV nucleic acid tests, reports an improved concordance among the various assays that have been optimized using the first WHO international calibration standard.CrossRefGoogle Scholar
23. 23.•
    Razonable RR et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56(11):1546–53. This study desribes the potential clinical application of a CMV nucleic acid test that has been standardized using the WHO calibrator. higher the viral load was associated with longer time to clinical disease resolution, while suppression of viral load to less than 137 IU/ml was associated with faster resolution of CMV disease.CrossRefGoogle Scholar
24. 24.•
    Durand CM et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;57(11):1550–9. This study desribes the potential clinical utility of the CMV nucleic acid test in the blood as a noninvasive method for the diagnosis of gastrointestinal CMV disease in transplant recipients.CrossRefGoogle Scholar
25. 25.•
    Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13 Suppl 4:93–106. This article serves as the guideline for the diagnsosis, prevention, and treatment of CMV infection and disease in solid organ transplantation, as endorsed by the American Society of Transplantation.CrossRefGoogle Scholar
26. 26.
    Humar A et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2005;5(5):1065–70.CrossRefGoogle Scholar
27. 27.
    Humar A et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427–31.PubMedCrossRefGoogle Scholar
28. 28.
    Bestard O et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(7):1793–805.CrossRefGoogle Scholar
29. 29.
    Cantisan S et al. Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(3):738–45.CrossRefGoogle Scholar
30. 30.
    Lisboa LF et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195–200.PubMedCrossRefGoogle Scholar
31. 31.•
    Manuel O et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56(6):817–24. This study describes the potential utility of an interferon-gamma release assay for assessing the risk of late-onset CMV disease in high-risk CMV D+/R− solid organ transplant recipients.CrossRefGoogle Scholar
32. 32.
    Hodson EM et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2, CD003774.PubMedGoogle Scholar
33. 33.
    Paya C et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(4):611–20.CrossRefGoogle Scholar
34. 34.
    Kalil AC et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transplant: Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2012;18(12):1440–7.CrossRefGoogle Scholar
35. 35.
    Julian KG et al. Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. Transplant Proc. 2013;45(9):3414–7.PubMedCrossRefGoogle Scholar
36. 36.
    Sund F et al. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 2013;28(3):758–65.CrossRefGoogle Scholar
37. 37.
    Palmer SM et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–9.PubMedCrossRefGoogle Scholar
38. 38.
    Hammond SP et al. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transplant Infect Dis: Off J Transplant Soc. 2013;15(2):163–70.CrossRefGoogle Scholar
39. 39.
    Wiita AP et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transplant Infect Dis: Off J Transplant Soc. 2012;14(3):248–58.CrossRefGoogle Scholar
40. 40.
    Boivin G et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2012;53(3):208–13.CrossRefGoogle Scholar
41. 41.
    Owers DS et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2, CD005133.PubMedGoogle Scholar
42. 42.
    Greiner M et al. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. Infection. 2012;40(6):669–75.PubMedCrossRefGoogle Scholar
43. 43.
    Mendez-Eirin E et al. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy. Transplant Proc. 2012;44(9):2660–2.PubMedCrossRefGoogle Scholar
44. 44.
    Casquero S et al. Preemptive therapy in the prevention of cytomegalovirus disease in high- and low-risk heart transplant recipients. Transplant Proc. 2012;44(7):2113–4.PubMedCrossRefGoogle Scholar
45. 45.
    Lautenschlager I et al. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2013;57(1):50–3.CrossRefGoogle Scholar
46. 46.
    Martin-Gandul C et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2013;56(1):13–8.CrossRefGoogle Scholar
47. 47.
    Onor IO et al. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transplant Int: Off J Eur Soc Organ Transplant. 2013;26(6):592–600.CrossRefGoogle Scholar
48. 48.
    Manuel O et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(9):2402–10.CrossRefGoogle Scholar
49. 49.
    Minces, L.R., et al., Ganciclovir-resistant cytomegalovirus (CMV) infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrobial agents and chemotherapy, 2013.Google Scholar
50. 50.
    Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.PubMedCentralPubMedCrossRefGoogle Scholar
51. 51.
    Yost, S.E., et al., Panresistant Cytomegalovirus in a Kidney Transplant Recipient. Pharmacotherapy, 2013.Google Scholar
52. 52.
    Germi, R., et al., Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral research, 2013.Google Scholar
53. 53.•
    Marty FM et al. CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. N Engl J Med. 2013;369(13):1227–36. This study provides early indication about the safety and efficacy of liposomal cidofovir for the prevention of infection in transplantation.PubMedCrossRefGoogle Scholar
54. 54.
    Winston DJ et al. Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial. Am J Transplant. 2012;12(11):3021–30.PubMedCrossRefGoogle Scholar
55. 55.
    Winston DJ et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2012;12(11):3021–30.CrossRefGoogle Scholar
56. 56.
    Alain S et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc. 2013;45(4):1603–7.PubMedCrossRefGoogle Scholar
57. 57.•
    Stoelben, S., et al., Pre-emptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transplant international : official journal of the European Society for Organ Transplantation, 2013. This study describes the early evidence for the efficacy and safety of a novel drug, letermovir, for the management of CMV infection after transplantation.Google Scholar
58. 58.
    Zurcher S et al. Sensitive and rapid detection of ganciclovir resistance by PCR based MALDI-TOF analysis. J Clin Virol: Off Publ Pan Am Soc Clin Virol. 2012;54(4):359–63.CrossRefGoogle Scholar
59. 59.
    Kharfan-Dabaja MA et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290–9.PubMedCrossRefGoogle Scholar
60. 60.
    Pass RF et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191–9.PubMedCentralPubMedCrossRefGoogle Scholar
61. 61.
    Bedino, G., et al., The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. International urology and nephrology, 2012.Google Scholar
62. 62.
    Posadas Salas, M.A., et al., Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transplant infectious disease : an official journal of the Transplantation Society, 2013.Google Scholar